Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Sideras
Kostandinos
K
Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.
Menefee
Michael E
ME
Burton
Jill K
JK
Erlichman
Charles
C
Bible
Keith C
KC
Ivy
S Percy
SP
D018249:Adenoma, Oxyphilic / Q000188:drug therapy; D000328:Adult; D001741:Black or African American; D005260:Female; D006197:Hair / Q000187:drug effects / Q000473:pathology; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced*; D007191:Indazoles; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy
D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib